AR029199A1 - Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas - Google Patents

Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas

Info

Publication number
AR029199A1
AR029199A1 ARP000106398A ARP000106398A AR029199A1 AR 029199 A1 AR029199 A1 AR 029199A1 AR P000106398 A ARP000106398 A AR P000106398A AR P000106398 A ARP000106398 A AR P000106398A AR 029199 A1 AR029199 A1 AR 029199A1
Authority
AR
Argentina
Prior art keywords
partial
pharmaceutical compositions
derivatives
adenosina
heterociclico
Prior art date
Application number
ARP000106398A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of AR029199A1 publication Critical patent/AR029199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los derivados de adenosina modificado con N6 heterocíclicos 5' que son los agonistas parciales o completos del receptor A1, y como tales, son utiles para modificar la actividad cardíaca, modificar la funcion del adipocito, tratar los trastornos del sistema nervioso central y, tratar los trastornos diabéticos y la obesidad en mamíferos y, especialmente humanos, de acuerdo a la formula general (1), donde las definiciones de los sustituyentes se proveen en la memoria descriptiva. Sus usos y composiciones farmacéuticas.
ARP000106398A 1999-12-03 2000-12-01 Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas AR029199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
AR029199A1 true AR029199A1 (es) 2003-06-18

Family

ID=23803455

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106398A AR029199A1 (es) 1999-12-03 2000-12-01 Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas

Country Status (25)

Country Link
US (2) US6605597B1 (es)
EP (1) EP1233973B1 (es)
JP (1) JP4021195B2 (es)
KR (1) KR100484988B1 (es)
CN (1) CN1152042C (es)
AR (1) AR029199A1 (es)
AT (1) ATE254133T1 (es)
AU (3) AU4138701A (es)
BR (1) BR0016126A (es)
CA (1) CA2389264C (es)
CZ (1) CZ20013705A3 (es)
DE (1) DE60006576T2 (es)
DK (1) DK1233973T3 (es)
ES (1) ES2208437T3 (es)
HK (1) HK1047941A1 (es)
HU (1) HUP0500455A2 (es)
IL (1) IL145903A (es)
MX (1) MXPA01011113A (es)
NO (1) NO20015373L (es)
NZ (1) NZ514777A (es)
PT (1) PT1233973E (es)
TR (2) TR200301971T4 (es)
TW (1) TWI249536B (es)
WO (2) WO2001040243A2 (es)
ZA (1) ZA200204380B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
KR20040084929A (ko) * 2002-02-19 2004-10-06 씨브이 쎄러퓨틱스, 인코포레이티드 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
CA2515068A1 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
EP1685135B1 (en) 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
ES2383525T3 (es) * 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
CA2627319A1 (en) * 2005-11-30 2007-06-07 Prakash Jagtap Purine derivatives and methods of use thereof
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2007107598A1 (en) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
EP2265125B1 (en) * 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
EP3715345B8 (en) 2012-07-25 2024-05-29 Bausch + Lomb Ireland Limited Preparation of lfa-1 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5789419A (en) * 1994-06-09 1998-08-04 Ss Pharmaceutical Co., Ltd. 4-quinolinone derivative or salt thereof
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
EP1233973A1 (en) 2002-08-28
NO20015373L (no) 2001-11-29
CZ20013705A3 (cs) 2002-04-17
TR200103129T2 (tr) 2002-10-21
CN1378550A (zh) 2002-11-06
AU4138701A (en) 2001-06-12
AU1811701A (en) 2001-06-12
KR100484988B1 (ko) 2005-04-22
KR20030032907A (ko) 2003-04-26
ATE254133T1 (de) 2003-11-15
JP4021195B2 (ja) 2007-12-12
WO2001040246A1 (en) 2001-06-07
WO2001040243A2 (en) 2001-06-07
CA2389264C (en) 2007-03-06
PT1233973E (pt) 2004-02-27
HUP0500455A2 (hu) 2005-08-29
ZA200204380B (en) 2003-06-25
MXPA01011113A (es) 2002-06-04
TWI249536B (en) 2006-02-21
US20050054605A1 (en) 2005-03-10
ES2208437T3 (es) 2004-06-16
DK1233973T3 (da) 2004-02-16
NO20015373D0 (no) 2001-11-02
IL145903A (en) 2006-04-10
TR200301971T4 (tr) 2004-01-21
EP1233973B1 (en) 2003-11-12
AU761029B2 (en) 2003-05-29
NZ514777A (en) 2004-01-30
HK1047941A1 (zh) 2003-03-14
WO2001040243A3 (en) 2001-12-13
CN1152042C (zh) 2004-06-02
BR0016126A (pt) 2002-08-06
US6605597B1 (en) 2003-08-12
AU7938301A (en) 2002-03-21
DE60006576T2 (de) 2004-09-16
CA2389264A1 (en) 2001-06-07
JP2003516325A (ja) 2003-05-13
DE60006576D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
AR029199A1 (es) Derivados de adenosina n6 heterociclico 5'-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas
AR029198A1 (es) Derivados de adenosina 8-modificados heterociclicos n6, composiciones farmaceuticas que los comprenden y el uso de dichos derivados para la manufactura de medicamentos
AR029025A1 (es) Derivados de adenosina n6 heterociclicos 5' modificados, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de un medicamento
ECSP003713A (es) Derivados de purina
ECSP003712A (es) Derivados de la purina
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
BR0207952A (pt) Moduladores da atividade de receptores de quimiocina
ATE187726T1 (de) A1 adenosin rezeptor agonisten und antagonisten
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
DE60318219D1 (de) PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
DE69626705D1 (de) A1 adenosin rezeptor agonisten und antagonisten
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
PA8458301A1 (es) 2-aminopiridinas con sustituyentes alcoxi ramificados
UY27177A1 (es) Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina.
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure